Verdiva Bio Terminated Mid-Stage Weight-Loss Study
The company ended a Phase II trial investigating its VRB-101 drug for maintenance.
Updated on Oct. 13, 2026 in Weight Loss
Live Poll
Do you trust pharmaceutical companies to prioritize patient health outcomes over their own market competitiveness?
Verdiva Bio has officially terminated a Phase II clinical study that evaluated the efficacy of its drug, VRB-101, for weight-loss maintenance. The study was designed to treat individuals who had previously achieved at least a 10% reduction in body weight while using other medications.
Why it matters
The company chose to end this specific investigation as part of a refined clinical development strategy. Verdiva Bio continues to prioritize other research efforts, including the development of VRB-101 as a monotherapy.
The terminated Phase II study focused on participants who lost at least 10% of their body weight on Wegovy or Zepbound. Verdiva previously raised $411 million in funding upon its launch in early 2025.
The players
Verdiva Bio
This biotechnology firm focuses on the development of weight-loss pharmaceuticals and therapies.
The details
The trial specifically targeted participants with a history of obesity or overweight who had successfully maintained weight loss. While this study is closed, the company has completed the 206-participant Phase IIb EVOLVE-2 study for VRB-101 as a monotherapy.
Timeline
Verdiva Bio launched with $411 million in funding in early 2025.
A Phase I trial assessing VRB-103 and VRB-101 launched in July 2026.
The study termination was reported on October 13, 2026.
Health Landscape
This decision marks a strategic refinement as the company moves away from maintenance-specific trials. It reflects a shift in the broader healthcare landscape where developers prioritize monotherapy efficacy over niche maintenance protocols.
The termination of this trial limits the immediate availability of new maintenance-focused treatment options for individuals currently using Wegovy or Zepbound. Patients should consult their healthcare providers to discuss ongoing care plans and established treatment guidelines.
The takeaway
Weight-loss patients should continue to rely on established, FDA-approved medications and maintain open communication with their doctors regarding long-term maintenance. Clinical trials for new treatments are highly experimental, and shifts in company strategy are common in the drug development process.
What happens next
Verdiva Bio will provide an update on the results of the EVOLVE-2 clinical trial at a future date.
Further reading
For more information on the evolving sector, visit the Weight Loss section.
Live Poll
Do you trust pharmaceutical companies to prioritize patient health outcomes over their own market competitiveness?
